What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

Senator Introduces Bill to Rid Switching Study Requirements for Interchangeability

November 22nd 2022

By Skylar Jeremias

The Biosimilar Red Tape Elimination Act will seek to increase patient access to biosimilars by reducing switching study requirements for companies to obtain interchangeability designations.

Biocon’s Biosimilars Revenue Up 34% YoY

November 21st 2022

By Skylar Jeremias

In Biocon’s second quarter of fiscal year 2023 earnings report, revenues were up 23% year over year (YoY) for the company, largely in thanks to the 34% increase in revenues for biosimilars and accounting for 42% of the total company revenue.

Dr Ryan Haumschild Explains How Technology Can Help Practices Juggle Multiple Biosimilars

November 20th 2022

By Skylar Jeremias

Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.

Administration for Pegfilgrastim Biosimilars Should Minimize Clinic Visits, Consider Patients’ Preferences

November 19th 2022

By Deana Ferreri, PhD

A review explored the 3 main administration options for pegfilgrastim biosimilars, finding that providers should consider the ease and frequency to which patients will need to travel to a clinic for administration as well as their preferences when choosing a mode of administration.

The Top 5 Biosimilar Articles for the Week of November 14

November 18th 2022

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of November 14, 2022.

Biosimilar Check-in: PBM to Cover Adalimumab Biosimilars; World’s First Denosumab Biosimilar; Organon Launches in Canada

November 17th 2022

By Skylar Jeremias

Organon Canada launches 2 biosimilars referencing Avastin (bevacizumab) and Herceptin (trastuzumab), China became the first country to approve a denosumab biosimilar, and Optum Rx, a large pharmacy benefit manager (PBM), said that it will add adalimumab biosimilars to formulary.

Dr Ryan Haumschild Speaks on How Local, National Policy Can Increase Confidence in Interchangeability

November 16th 2022

By Skylar Jeremias

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, describes how local health policy initiatives can help providers and patients feel more comfortable with the idea of interchangeable biosimilars.

The European Union Gains Another Ranibizumab Biosimilar

November 15th 2022

By Skylar Jeremias

The European Union has approved a third biosimilar referencing Lucentis (ranibizumab), STADA Arzneimittel and Xbrane BioPharma’s Ximluci, for the treatment of retinal conditions.

In Sight: The Future of Biosimilars in Ophthalmology Care

November 14th 2022

A moderated digital open forum facilitated an interactive discussion among health care professionals, health system executives, health care payers, and health policy influencers about promise and the barriers to the expanded use of biosimilars in ophthalmic applications.

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

November 14th 2022

By Robert Popovian, PharmD, MS

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.